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Abstract: All forms of chronic kidney disease (CKD) eventually lead to renal fibrosis irrespective of its origin. It is 
generally characterized by an excessive accumulation and deposition of extracellular matrix (ECM) and to date no ideal 
treatment has been established. Bian-Zheng-Lun-Zhi (syndrome differentiation and treatment), a classic feature of 
traditional Chinese Medicine (TCM), is a unique method used to diagnose and treat the pathology of a disease. Zheng 
(syndrome) is used to demonstrate the nature of a disease completely in an extensive and specific manner. Chinese herbal 
formulas are determined according to TCM theory and this review highlights these formulas and suggests possible 
mechanism for their use in the treatment of renal fibrosis. 
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1. INTRODUCTION 
Chronic kidney disease (CKD) prevalence is estimated to 
be 8-16% and is becoming a major public health concern.. 
Moreover, it is ranked the third highest for years of life lost 
due to premature mortality (82%), behind AIDS and diabetes 
mellitus [1-3]. Renal fibrosis is the final, common 
pathological feature of every progressive CKD regardless of 
etiology [4]. The molecular mechanisms of renal fibrosis are 
associated with inflammatory cell infiltration, myofibroblast 
proliferation and epithelial-mesenchymal transition (EMT), as 
well as extracellular matrix (ECM) overproduction [5, 6]. 
However, these complex mechanisms responsible for renal 
fibrosis are still poorly understood. The existing therapies are 
not ideal for the treatment of CKD and hence there is an urgent 
need to explore the pathophysiological mechanisms 
underlying renal fibrosis and to discover safe and new 
strategies for its treatment. 
Recently, Traditional Chinese Medicine (TCM) has been 
increasingly used in the treatment of renal disorders  due to its 
clinical efficacy and safety [7]. Bian-Zheng-Lun-Zhi 
(syndrome differentiation and treatment) is one of the most 
fundamental characteristics of TCM, which is a unique 
method to diagnose and treat the pathology of a disease. The 
Bian-Zheng entails analyzing, inducing, judging and 
summarizing the clinical data of symptoms and signs by four  
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diagnostic methods (inspection, listening and smelling, 
inquiry, taking pulse and palpation) to identify a certain Zheng 
(namely syndrome, a comprehensive description of the 
pathological process of a disease at a particular stage) [8-11]. 
This therapeutic principle is suggested according to the results 
of syndrome differentiation and the process is  named Lun-
Zhi, which is the standard methodology used in clinical 
treatment by TCM practitioners [9]. 
In the viewpoint of TCM, renal fibrosis is a pathological 
process due to a long-term imbalance between healthy qi and 
pathogenic factors leading to deficiency of healthy qi. 
Therefore, spleen-kidney deficiency (kidney-yin or yang 
deficiency) is an internal condition and a key factor in the 
development of renal fibrosis. This provides the main 
principle on which the treatment of renal fibrosis is based. 
Chinese herbal formulas are determined on the basis of TCM 
theory, which provides multiple functions with several 
medicines, and appropriate herbs can be prescribed with 
flexibility to suit the specific syndrome． 
Due to different factors and mechanisms involved in the 
pathogenesis of renal fibrosis, Chinese herbal formulas which 
display multi-channel and muti-target properties are being 
applied to clinical practice to treat renal fibrosis. Therefore, 
this review mainly focuses on the formulas which have been 
commonly used in patients and display potential antiﬁbrosis 
properties. Peer-reviewed articles were gathered by 
consulting the databases PubMed, Elsevier, Springer and 
Scholar and the search terms included renal, kidney, fibrosis, 




2    Journal Name, 2014, Vol. 0, No. 0 Principal Author Last Name  et al. 
 
2. THE PATHOPHYSIOLOGICAL MECHANISM OF 
RENAL FIBROSIS 
The histological characteristics of renal fibrosis include 
tubular atrophy and dilatation, interstitial leukocyte 
infiltration, increased fibroblasts and accumulation of 
collagen and ECM [12-14]. Therefore, an array of intra- and 
extracellular mechanism is critical in the prevention of renal 
fibrosis. With the help of molecular and cell biology 
technology and renal fibrosis animal models, it is generally 
accepted that the pathophysiology of renal fibrosis has been 
depicted as four overlapping phases namely: priming, 
activation, execution and progression [15, 16]. 
The first phase is cellular activation and injury stage, 
ongoing inflammatory stimulation triggers the activation of 
tubular epithelial cells and infiltration of inflammatory cells, 
including lymphocytes, monocytes/macrophages, dendritic 
cells and mast cells [17, 18]. The second phase is the 
fibrogenic signaling phase when several profibrotic cytokines 
are released accompanying the activation of matrix-producing 
cells. Recent studies have focussed on myofibroblasts, a 
subpopulation of activated fibroblasts, which are derived from 
bone-marrow, renal interstitial fibroblasts, vascular pericytes, 
endothelial and tubular cells, which contribute to the massive 
proliferation and excessive ECM accumulation [15, 19-21]. 
During the third phase, the excessive deposition of ECM, such 
as collagenⅠ, Ⅲ and fibronectin, leads to the development of 
renal fibrosis [22, 23]. In the last phase, the renal structure and 
function gradually disappear with sustaining ECM 
accumulation, which results in the majority of the undesirable 
consequences of fibrosis.  
Renal fibrosis is an enormously complex, dynamic 
process that involves almost all types of renal cells and the 
infiltrated cells. Nevertheless the mechanisms implicated in 
renal fibrosis are still not entirely clear which raises the 
question of how to control renal fibrosis. 
3. CHINESE HERBAL FORMULAS FOR TREATING 
RENAL FIBROSIS  
Many beneficial medicinal formulas, including patent 
medicines, classic prescriptions and empirical recipes, are 
extensively documented in the TCM systems in many 
cultures. Among these, there are plenty of Chinese herbal 
formulas with anti-fibrotic effects which have been used for 
the treatment and prevention of renal fibrosis. Here are some 
typical examples, and others are presented in Table1.  
  Niaoduqing granule (NDQG), also known as Uremic 
Clearance granules, includes: radix et rhizoma rhei, radix 
astragali, radix glycyrrhizae, rhizoma atractylodis 
macrocephalae, radix polygoni multiflori preparata, Flos 
chrysanthemi, radix salviae miltiorrhizae, radix codonopsis, 
radix bupleuri, cortex mori, radix sophorae flavescentis, radix 
paeoniae alba, herba plantaginis, rhizoma pinelliae, poria 
and rhizoma ligustici. This is the first TCM approved by the 
State Food and Drug Administration (SFDA, China) for the 
treatment of CKD as a Chinese patent medicine, and has been 
widely used in clinical practice for the lowering of serum 
creatinine (Scr), blood urea nitrogen (BUN) and renal 
protection [24-26]. NDQG therapeutical effects are due to  the 
promotion of ECM degradation, regulation of  MMP-2/TIMP-
1 balance and the inhibition  of TGF-β1/smad signal pathway 
in an unilateral ureteral obstruction (UUO) model. NDQG 
also can prevent EMT and suppress vlmentin and α-SMA 
expression, as well as restore E-cadherin expression thus 
confirming that NDQG may be a promising agent of anti-
fibrosis [27, 28].   
 Huangqi decoction (HQD), which comprises of 
Astragalus, Poria, Trichosanthes, Ophiopogon, Schisandra, 
Licorice and Rehmannia, is originally recorded in Yang 
shiying’s Renzhai Zhizhi Fanglun at Northern Song Dynasty. 
It is one of the most classic recipes in the clinical treatment of 
CKD and according to the TCM theory, HQD can tonify 
kidney-qi [29, 30]. Recently, significant progress has been 
made in the molecular mechanisms responsible for the 
treatment of CKD by HQD. It was reported that HQD can 
reverse structural and functional alterations in 5/6 
nephrectomized rats by inhibiting NAPDH oxidase 
expression, ROS production and promoting NO production 
[31]. In addition, HQD ameliorates renal fibrosis in an (UUO) 
model through not only inhibiting transforming growth factor-
β1 (TGF-β1)/Smad signal pathway, but also by activating 
Wnt/β-catenin signal pathway [29, 32]. 
   Kangxianling granule (KXLG), which is composed of 
Radix salviae miltiorrhiae, prepared rhubarb, angelica, 
Achyranthes and peach kernel, is an empirical formula which 
was developed to treat CKD as well as early and mid-stage 
renal fibrosis by Shuguang Hospital of Shanghai University 
of TCM [33-35]. Based on previous studies, KXLG prevents 
renal fibrosis  probably by inhibiting TGF-β, Smads, 
angiotensin Ⅱ, tumor necrosis factor-α (TNF-α), nuclear 
factor-κB (NF-κB), and eventually leads to a series of changes 
that: 1) inhibit tubular epithelial cell apoptosis; 2) inhibit 
myofibrolasts trans-differentiation; 3) inhibit the proliferation 
of inflammatory cells and  4) reduce the EMT transition [36, 
37].  
4. SUGGESTED MECHANISMS 
From the perspective of TCM, renal fibrosis is a leading 
cause of kidney-qi deficiency syndrome [38]. Therefore, 
tonifying kidney-qi, including invigorating kidney-yang and 
nourishing kidney-yin, is the main consideration in clinical 
practice. Yougui pill, a yang-tonic prescription, is used for the 
empirical treatment of renal fibrosis [39] and Fuzheng huayu 
formula is a SFDA approved anti-fibrotic medicine in China, 
which can not only activate blood and remove stasis, but also 
nourish yin [40].  
At present, extensive studies have been carried out to 
explore the molecular mechanisms of Chinese herbal formula 
in the treatment of renal fibrosis. The development and 
progression of renal fibrosis is primarily involved in the trans-
differentiation of kidney inherent cells such as mesangial, 
epithelial or endothelial cells or fibroblasts into 
myofibroblasts, and infiltration of inflammatory cells, 
regulated by numerous growth factors and cytokines, 
eventually leading to ECM excessive deposition [41, 42]. 
Emerging evidence indicates that about 30% of 
myofibroblasts are generated via EMT (epithelial-
mesenchymal transition) pathway  in diseased kidney [43]. 
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Hence epithelial cells lose intercellular adhesion molecules E-
cadherin and synthesize α-smooth muscle actin (α-SMA) as 
well as actin reconstruction, which plays a crucial role in renal 
fibrosis [44-46]. Qizhuxiezhuo Fang protects kidney against 
fibrosis through inhibiting EMT transition via upregualting E-
cadherin and downregulating α-SMA [47].  
It is reported that EMT can be initiated by transforming 
growth factor-β1 (TGF-β1) [48] a well known cytokine, 
which is regarded as a central mediator of renal fibrosis [49]. 
There is considerable evidence which suggests that TGF-β1 is 
substantially increased in the injured kidney in both animal 
disease models and CKD patients [50, 51]. TGF-β1 not only 
induces proliferation, migration of different types of renal 
cells, but also regulates various ECM proteins synthesis and 
degradation [52, 53].  
In addition to these, previous studies have suggested that 
TGF-β1 can decrease the activation of MMPs, induce the 
expression of connective tissue growth factor (CTGF) and 
platelet derived growth factor-B (PDGF-B) [54-56]. MMPs 
are a large family of zinc-dependent endopeptidases that play 
a central role in the degradation of ECM, while the activity of 
MMPs can be down regulated by tissue inhibitors of 
metalloproteinases (TIMPs) [57]. Among these, gelatinases 
(MMP-2, -9) predominantly degrade collagen, a major 
component of ECM [58, 59]. CTGF has been shown to 
promote myfibroblast activation and ECM accumulation [60] 
whilst PDGF is known to stimulate glomerular mesangial cell 
proliferation and ECM deposition [61, 62].  
The current evidence shows that TGF-β1/Smads signal 
pathway is the most classic signaling pathway in the 
progression of  renal fibrosis [63]. Consistent results from 
numerous studies indicate that TGF-β1/Smads signal pathway 
can be inhibited by decreasing Smad2/3 and increasing Smad7 
and these may have antifibrosis effects [64, 65]. Above of all, 
targeting the TGF-β1downstream effectors or the signaling 
that mediates its fibrogenic action will become a new therapy 
in the treatment of renal fibrosis, and several Chinese herbal 
formulas are being developed for this purpose such as Shenqi 
Wan and Tongxin Luo [66, 67].  
Current research shows that renal fibrosis also can be 
considered as an inflammatory process which is associated 
with the increased expression of tumor necrosis factor- α 
(TNF-α) and with the activation of NF-κB [68, 69]. TNF-α 
participates in the infiltration and activation of inflammatory 
cells and in the transformation of epithelial cells and 
fibroblasts into myofibroblasts [52]. Decreased NF-κB levels 
has been reported to attenuate renal injury and inflammation 
in different animal models of CKD [70, 71]. Therefore, anti-
inflammation agents are attractive therapeutic target for 
attenuating the inflammatory process, such as Fuzheng Huayu 
Formula [40]. 
Oxidative stress in progressive renal disease has been 
highlighted by emerging data in which antioxidant 
therapeutics target mitochondrial reactive oxygen species 
(ROS) and especially ameliorate renal fibrosis lesions in the 
experimental models [72]. Recent studies indicate that TGF-
β1 stimulates the generation of ROS by activating 
nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase that activates p38 mitogen-activated protein kinases 
(MAPK), Jun N-terminal kinase (JNK), extracellular-signal-
regulated kinase (ERK) signaling [73]. Some Chinese herbal 
formulas could prevent renal fibrosis via antioxidative stress, 
such as Wenpitang Hab Wuling san [74]. 
From what has been discussed above, the underlying 
mechanisms of Chinese herbal formulas to prevent renal 
fibrosis could inhibit renal cell proliferation, inflammatory 
cell infiltration and reduce oxidative stress via stimulating or 
suppressing growth factors, cytokines, proteins, as well as 
modulating signaling pathways. However, more evidence is 
needed to confirm or investigate new mechanisms for treating 
renal fibrosis. The common pathway involved in the treatment 
of renal fibrosis is shown in Fig.1.  
5. CONCLUSIONS AND PERSPECTIVES 
CKD is an increasingly common condition with limited 
treatment options that is placing a major ﬁnancial and 
emotional burden on the community. Renal fibrosis is also 
most relevant with the rate of progression of renal dysfunction 
[75]. The pathogenesis of renal fibrosis can be artificially 
divided into four phases. However, such a division is 
arbitrary, as in reality renal fibrogenesis is a dynamic process 
in which many of these events occur concomitantly [16], 
hence, using a single-target strategy for the renal fibrosis 
treatment is not reliable. At present, more attention has been 
focused on TCM with its well defined and established 
therapeutic system. Bian zheng lun zhi, the classic theory of 
TCM, provides a multi-link and muti-path comprehensive 
method for preventing and treating renal fibrosis.  Chinese 
herbal formulas combine different herbal compounds to 
increase or promote therapeutic effectiveness, minimize 
toxicity and side effects, and optimize the therapeutic effects 
of each component, which can provide a safe and effective 
therapy in the treatment of renal fibrosis.  
Currently, limited experimental studies involving the level 
of cytology and protein expression have been conducted on 
Chinese herbal formulas. This article has presented and 
analyzed the Chinese herbal formulas effective against renal 
fibrosis and their suggested mechanisms have been outlined 
Chinese herbal formulas can act as anti-fibrosis agents due to 
their anti-proliferative, anti-inflammatory and anti-oxidant 
properties and have been applied clinically. However, it is still 
necessary to search for novel formulas for treating renal 
fibrosis. Although several distinct targets and common 
molecular signal pathways have been disclosed, the details of 
the anti-fibrosis mechanisms of the Chinese herbal formulas 
involved need to be clarified further. Furthermore, the active 
substances of the Chinese herbal formulas, their synergy with 
a variety of prescription drugs and interactions with new 
pharmaceuticals need to be investigated further.  
In summary, the focus of future clinical research should 
be to combine TCM theory with the latest medical research 
and in order to explore more effective and less toxic formulas, 
investigate their underlying mechanisms, and develop 
effective new dosage forms. 
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Table 1 The Chinese herbal formulas from medicinal plants displaying anti-fibrosis properties 
Formula Constitute Model / Cell type Mechanism Ref 
Shenqi Detoxification 
Granule 
Radix Astragali, Salvia miltiorrhiza, Angelica 
sinensis, Rheum officinale, Gordon Euryale 
seed, Herba Ecliptate, radix semiaquilegiae, 
rhizoma imperatae, Prepared aconite lateral 
root, herb of Shorthorned Epimedium, 






Inhibit PDGF-B, CTGF expression 
and ET/NO. 
 
Inhibit TGF-β1-mediated EMT and 
TGF-β1-Smad-ILK signal pathway 
[76, 77] 
Shenqi wan Radix Rehmanniae, Cortex Moutan, 
Dogwood, Poria cocos, Yam, Alisma, Cassia 
Presl, Monkshood. 
Adenine induced model Inhibit TGF-β1/Smad signal 
pathway 
[66] 
Tongxinluo Panax ginseng, Ziziphus jujube Mill. var. 
spinosa, Paeonia lactiflora Pall, Santalum 
album, Dalbergia odorifera, Boswellia carteri 
Birdw, Borneolum syntheticum, Scolopendra 
subspinipes mutilans, Buthus martensii 
Karsch, Steleophage plancyi, Hirudo 
nipponica, Cryptotympana pustulata 
Fabricius 
High-fat induced DN 
model 
GECs and GMCs 
Inhibit the transfer of TGF-β1 from 




Salvia miltiorrhiza, Pollen Pini, Fermentation 
Mycelium Powder, Semen Persicae, Fructus 
Schisandrae Chinensis, Gynostemma 
Pentaphyllammak 





Salvia miltiorrhiza, Radix 
et Rhizoma Rhei, Cortex Moutan,  Semen 
Persicae, Radix Puerariae, Poria cocos 
(Schw.) Wolf, Semen Plantginis Asi-aticae, 
Arecae Pericarpium, Rehmannia glutinosa 
(Gaertn.) Li-bosch, Cornus officinalis Sieb. 
Et Zucc 
UUO Decrease TGF-β1,α-SMA and 




Radix et Rhizoma Rhei, Radix Aconiti 
Lateralis Preparata, Radix et Rhizoma Asari 
Aristolochic acid 
nephropathy model 
Decrease collagenⅠ, Ⅲ, increase 
MMP  
[79] 
            CRF: chronic renal failure; CTGF: connective tissue growth factor; DN: diabetic nephropathy; EMT: epithelial-mesenchymal transition; ET/NO: endothelin / nitric 
oxide; GECs: glomerular endothelial cells;  GMCs: glomerular messangial cells; ILK: integrin linked kinase; MMP: mitochondrial membrane potential; NF-κB: 
nuclear factor-Kappa B; PDGF-B: platelet-derived growth factor-B; p-IκB: phosphor-inhibitor-Kappa B;  RIF: renal interstitial fibrosis; TGF-β1: transforming 
growth factor-β1; TNF-α: tumor necrosis factor-α; UUO: unilateral ureteral obstruction; α-SMA: α-smooth muscle actin.  
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Formula Constitute Model / Cell type Mechanism Ref 
Qingxuan Jiangya 
Decoction 
Caulis Bambusae in Taeniam, Poria cocos, 
Gentiana scabra, Ligusticum chuanxiong 
Hort, Gastrodia elata, Scutellaria baicalensis, 
Coptis chinensis, Acorus calamus, 
OsDraconis,  Ostrea gigas, Gardenia 
jasminoides, Taxillus sutchuenensis, Prunella 
vulgaris 
Spontaneously 
hypertensive rat model 
Inhibit TGF-β1/Smad signal 





Radix et rhizoma rhei, Radix astragali, Radix 
glycyrrhizae, Rhizoma atractylodis 
macrocephalae, Radix polygoni multiflori 
preparata, Flos chrysanthemi, Radix salviae 
miltiorrhizae, Radix codonopsis, Radix 
bupleuri, Cortex mori, Radix sophorae 
flavescentis, Radix paeoniae alba, Herba 




Promote ECM degradation, 
regulate MMP-2/TIMP-1 balance 
and TGF-β1/Smad signal pathway 
[27] 
Qi Zhu Xie Zhou Fang Astragalus mongholicus, Atractylodes 
macrocephala, Coix lacryma-jobi, Pyrrosia 
lingua, Smilax glabra, Salvia Miltiorrhiza, 
Cuscuta chinensis, Isaria cicadae 




Decrease fibronectin , collagenⅠ, α-
SMA ,increase E-cadherin 
expression 
[47] 
Qishen Yiqi dropping 
pills 




Decrease TGF-β1, α-SMA, 
collagenⅠ, β-catenin 
[81] 
Huangqi Decoction Radix astragali, Wolfiporia extensa, Fructus 
trichosanthis, Radix ophiopogonis, Shizandra, 




Inhibit TGF-β1/Smad signal 
pathway 
Activate Wnt/β-catenin  
[29, 82] 
Yougui Pill Radix Rehmanniae Praeparata, Rhizoma 
Dioscoreae, Fructus Corni, Fructus Lycii, 
Semen Cuscutae, Cervi cornus colla, 
Eucommiae cortex, Cinnamomi cortex, Radix 




Inhibit TGF-β1/Smad signal 
pathway 
[39] 
TI-HU-YIN  UUO Decrease TGF-β1 expression [83] 
Huangkui capsule Abelmoschus manihot STZ induced DN model  Decrease TGF-β1, TNF-α, regulate 
p38MAPK/Akt pathway 
[84] 
Akt: serine-threonine kinase; BMP: bone morphogenetic protein; CTGF: connective tissue growth factor; DN: diabetic nephropathy; ECM: extracellular matrix; 
MAPK: mitogen-activated protein kinase; MMP: mitochondrial membrane potential; NRK52E: Normal kidney proximal tubular; NRK49F: renal fibroblast cells; 
STZ: streptozotocin;TGF-β1: transforming growth factor-β1; TIMP-1: tissue inhibitors of metalloproteinase-1; TNF-α: tumor necrosis factor-α; UUO: unilateral 
ureteral obstruction; α-SMA: α-smooth muscle actin. 
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Formula Constitute Model / Cell type Mechanism Ref 
Kangxianling granule Radix salviae miltiorrhiae, prepared rhubarb, 
angelica, Achyranthes, peach kernel 
UUO Inhibit TGF-β1/Smad signal 
pathway 
[37] 
Huluba Wan Trigonella foenum-graecum, Psoralea 
corylifolia 
STZ induced DN model Reduce oxidative stress via PKC-
α/NADPH oxidase signal pathway 
[85] 
Fufang Xue Shuan 
Tong capsule 
Panax Notoginseng, Radix Astragali, Radix 
Salvia Miltiorrhizae, Radix Scrophulariaceae 
STZ induced DN model Inhibit BMP2- TGF-β-CTGF 
signal pathway 




Codonopsis pilosulae radix, Salviae 
miltiorrhizae radix, Pinelliae rhizome, Coptis 
rhizome, Epimedii herba, Rhei radix et 
rhizoma, Perillae folium, Glycyrrhizae radix, 
Artemisiae capillaris herba, Alismatis 
rhizome, Poria, Atractylodis macrocephalae 






Inhibit TGF-β1/Smad signal 
pathway 
 





Astragali radix, Trigonellae semen, (Rhei 
radix et rhizoma, Vaccariae semen, Curcumae 
rhizoma, Smilacis glabrae rhizoma, Coptidis 
rhizoma 
5/6 nephrectomy rats Decrease TGF-β1, α-SMA, 
increase E-cadherin expression 
[89] 
Shenkang injection Rhubarb, Astragalus, Radix Salviae 
Miltiorrhizae, Carthami Flos 
5/6 nephrectomy induced 
CKD model 
Reduce oxidative stress through 





Radix et Rhizoma Rhei, Poria, Radix 
Pseudostellariae, Radix Astragali, Rhizoma 
Atractylodis Macrocephalae, 
Fructus Mori, Serissa foetida, Crataegus 
pinnatifida, Angelica sinensis 
5/6 nephrectomy Inhibit renal tubular epithelial cell 
apoptosis  through inhibiting TGF-
β1-ROS-MAPK signaling  
[73] 
Danggui Buxue Tang Radix Angelicae Sinensis, Radix Astragali UUO Decrease NLRP3 inflammasome 
and IL-1β expression 
[91] 
ERK1/2: extracellular signal-regulated kinase 1/2; JNK1/2: c-Jun N-terminal kinase 1/2; IL-1β: interleukin-1β; MAPK: mitogen-activated protein kinase; NF-κB: 
nuclear factor-Kappa B; NLRP3: NOD-like receptors family pyrin domain-containing 3; ROS: reactive oxygen species; STZ: streptozotocin; TGF-β1: transforming 
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